Prostate cancer in African American men

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 3, 1998, Pages 109-118

  Moul, J W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Black race; Cancer; Prostate

Indexed keywords

EID: 3142531243     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500222     Document Type: Article

References (91)

1. Boring CC, Squires TS, Health CW. Cancer statistics for African Americans. CA Cancer J Clin 1993; 43: 7-17.
2. Morton RA. Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994; 44: 637-645.
3. Cooper R, David R. The biologic concept of race and the application to public health and epidemiology. J Health Polit Policy Law 1986; 11: 97-116.
4. Osborne NG, Feit MD. The use of race in medical research. JAMA 1992; 267: 275-279.
5. Witzig R. The medicalization of race: Scientific legitimization of a flawed social construct. Ann Intern Med 1996; 125: 675-679.
6. Robinson SB, Ashley M, Haynes MA. Attitudes of African Americans regarding screening for prostate cancer. J Nat Med Assoc 1996; 88: 241-246.
7. Robinson SB, Ashley M, Haynes MA. Attitudes of African Americans regarding prostate cancer clinical trials. J Comm Health 1996; 21: 77-87.
8. Powell IJ et al. Outcomes of African American men screened for prostate cancer. The Detroit Education and Early Detection study. J Urol 1997; 158: 146-149.
9. Moul JW. Editorial Comment to Outcomes of African American men screened for prostate cancer: The Detroit Education and Early Detection Study. J Urol 1997; 158: 149.
10. Mouton CP. Special health considerations in African-American elders. Am Family Physician 1997; 55: 1243-1253.
11. McCoy-Sibley RI, Sibley AF. Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans. J Nat Med Assoc 1997; 89: 318-323.
12. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Eng J Med 1995; 333: 1401-1405.
13. Catalona WJ. Screening for prostate cancer (Letter). N Eng J Med 1996; 334: 666-667.
14. Mettlin C et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-46.
15. American Urological Association Early detection of prostate cancer and use of transrectal ultrasound, in AUA (ed): American Urological Association 1992 Policy Statement Book,: pp. 4-20: American Urological Association, 1992, Baltimore, MD.
16. US Preventive Services Task Force. Screening for prostate cancer. In: Guide to Clinical Preventive Services 2nd edn.Williams and Wilkins: Baltimore, MD, 1996: 119-134.
17. American College of Physicians. Screening for Prostate Cancer. Annals of Internal Medicine 1997; 126: 480-484.
18. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954.
19. Barry MJ, Robert RG. Indications for PSA testing. JAMA 1997; 277: 955.
20. Roach J et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group Protocols (1976-1985) Int J Radiat Oncol Bio Phys 1992; 24: 441-449.
21. Optenberg SA et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 1995; 274: 1599.
22. Fowler JE, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol 1996; 156: 133-136.
23. Vijayakumar S et al. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidermiol Bio-markers Prev 1992; 1: 541-545.
24. Staggers FM et al. A profile of African-American participants in Prostate Cancer Awareness Week (PCAW) 1992. J Urol 1994; 151: 291 (Abstract 255).
25. Bullock A et al. Racial differences in prostate cancer detection and staging. J Urol 1994; 151: 291 (Abstract 257).
26. Moul JW, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J Am Med Assoc 1995; 274: 1277-1281.
27. Vijayakumar S et al. Prostate specific antigen levels in African Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am 1996; 2: 225-233.
28. Diantoni EP, et al. Age and race specific references ranges for prostate-specific antigen from a large, community-based study. J Urol 1996; 155: 374 (Abstract 253).
29. Henderson RJ et al. Prostate specific antigen (PSA) and PSA density (PSAD) are higher in African Americans without prostate cancer: Results of 526 patients. J Urol 1996; 155: 376 (Abstract 262).
30. Asbell SO, Vijayakumar S. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Prostate 1997; 31: 42-46.
31. McCammon KA, Schelhammer PF, Wright GL, Lynch DF. Age-specific PSA levels in African Americans. J Urol 1996; 155: 426 (Abstract 461).
32. Smith DS, Catalona WJ, Bullock AD. Operating characteristics of prostate cancer screening tests in African American and white men. J Urol 1996; 155: 376 (Abstract 264).
33. Morgan TO, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-310.
34. Oesterling JE et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860.
35. Littrup PJ Editorial: Prostate cancer in African-American Men Prostate 1997 31: 139-141.
36. Littrup PJ, Sparschu RA. Transrectal ultrasound and prostate cancer risks: The "tailored" prostate biopsy. Cancer 1995; 75: (suppl): 1805-1813.
37. McLeod DG. Response to Editorial Comments. Prostate 1997; 31: 142.
38. Moul JW. PSA thresholds for prostate cancer detection. JAMA 1997; 278: 699.
39. Carter HB et al. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456-1460.
40. Bullock AD, Harmon T, Smith DS, Basler JW. Prostate cancer screening in younger men. J Urol 1997; 157(suppl): 66 (Abstract 252).
41. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA 1997; 277: 1452-1455.
42. Smith DS, Catalona WJ, Bullock AD. Lower total PSA cutoffs for cancer screening in African-American men. J Urol 1997; 157(suppl): 160 (Abstract 618).
43. Pienta KT et al. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area, 1937 to 1987. Urology 1995; 45: 93-102.
44. Powell IH et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins. Urology 1997; 49: 726-731.
45. Moul, JW et al. Black race in an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal-access health care system. J Urol 1996; 155: 1667-1673.
46. Ibrahim GK, Coetzee LJ, Paulson DF. Outcomes of surgical therapy for clinically localized prostatic adenocarcinoma: Caucasians and Afro-Americans. J Urol 1995; 153(suppl): 504A (Abstract 1101).
47. Moul JW et al. Three dimensional (3D) computerized tumor volume determination in radical prostatectomy specimens from black and white patients. J Urol 1996; 155: 509 (Abstract 794).
48. Pettaway CA et al. Prostate specific antigen and tumor volume in African American and Caucasian men. A comparative study based on radical prostatectomy specimens. J Urol 1996; 155: 421 (Abstract 443).
49. Littrup P et al. Greater tumor involvement and higher Gleason scores on biopsies of African-American men. J Urol 1997; 157(suppl): 230 (Abstract 899).
50. Littrup P et al. Racial differences in the volume of Gleason score components: The potential for mathematical modeling of mortality differences and screening impact. J Urol 1997; 157(suppl): 65 (Abstract 250).
51. Paulson DF, Iselin CE. Surgical control of prostate cancer is equivalent in Afro-American and Caucasian males. J Urol 1997; 157(suppl): 53 (Abstract 202).
52. Powell IJ et al. Is prostate cancer testing at an earlier age among African-American men versus Caucasian men appropriate? J Urol 1997; 157 (suppl): 298 (Abstract 1160).
53. Levine RI, Wilchinsky M. Adenocarcinoma of the prostate: a comparison of the disease in blacks versus whites. J Urol 1979; 121: 761-762.
54. Page WF, Kuntz AJ. Racial and socioeconomic factors in cancer survival. Cancer 1980; 45: 1029-1040.
55. Hussain F et al. High grade adenocarcinoma of prostate in smokers of ethnic minority groups and Caribbean Island immigrants. Int J Radiat Oncol Biol Phys 1992; 24: 451-461.
56. Ruffer JE, Epstein BE, Peters T, Hanks G. Lower radiation dose may account for decreased survival of blacks with prostate cancer: results of the 1978 Patterns of Care Study. Int J Radiat Oncol Biol Phys 1991; 21(suppl 1): 212.
57. Natarajan N, Murphy G, Metlin C. Prostate cancer in blacks: an update from the American College of Surgeons' Patterns of Care Studies. J Surg Oncol 1989; 40: 232-236.
58. Austin JP et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol 1990; 13: 465-469.
59. Aziz H et al. Radiation-treated carcinoma of the prostate. Am J Clin Oncol 1988; 11: 166-171.
60. Kim JA, Kuban DA, El-Mahdi AM, Schellhammer PF. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Ther Radiol 1995; 194: 545-549.
61. Lawton CA, Byhardt RW, Murray KJ, Wilson IF. Docs race play a role in survival after radiation therapy? Radiology 1993; 189(P): 183 (Abstract).
62. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
63. Fowler JE, Bigler SA, Renfroe L, Dabagia MD. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol 1997; 158: 150-154.
64. Moul JW: Editorial comment to Fowler JE et al. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol 1997; 158: 154.
65. Sakr WA et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993 150: 379-385.
66. Sakr WA et al. Epidemiology of high grade intraepithelial neoplasia. Path Res Prac 1995; 191: 838-841.
67. Ross R et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76: 45.
68. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences health. Steroids 1992; 57: 72.
69. Ross RK et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887.
70. Coetzee GA, Ross RK. Re: Prostate cancer and the androgen receptor. Letter to the Editor. J Natl Cancer Inst 1994; 86: 872.
71. Hakimi JM et al. Androgen receptor CAG (glutamine) and GGC (glycine) repeat lengths as potential risk factors for prostate cancer. Amer Assoc Cancer Res 1996; 37: 258.
72. Giovannucci E et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320-3323.
73. Jackson MA et al. Characterization of prostate carcinoma amongst blacks: A continuation report. Cancer Treat Rep 1977; 61: 167-172.
74. Osegbe DM. Prostate cancer in Nigerians: Facts and non-facts. J Urol 1997; 157: 1340-1343.
75. Whittemore AS et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652.
76. Powell IJ. Prostate cancer and African American Men. Oncology 1997; 11(5): 599-607.
77. Wang Y et al. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low fat diet. J Natl Cancer Institute 1995; 87: 1456-1462.
78. Gao X et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995; 46: 227-237.
79. Gann PH et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121-126.
80. Moul JW et al. Infrequent ras oncogene mutations in human prostate cancer. Prostate 1992; 20: 237-338.
81. Kuhn EJ et al. Expression of the c-erb-2 oncoprotein in prostate cancer. J Urol 1993; 150: 1427-1433.
82. Moul JW et al. Cathepsin-D and Epidermal growth factor receptor (EGFR), immonohistochemistry does not predict recurrence of prostate cancer patients undergoing radical prostatectomy. J Urol 1966; 155: 982-985.
83. Bauer JJ et al. p53 protein expression is an independent prognostic marker in clinically localized prostate cancer patients. Clin Cancer Res 1995; 1: 1295-1300.
84. Bauer JJ et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996; 156: 1511-1516.
85. Gaddipatti JP et al. Mutations of the p16 gene product are rare in prostate cancer. Prostate 1997; 30: 188-194.
86. Bettencourt M et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064-1068.
87. Sarkar FH et al. Over-expression of ERB-B2 gene in the prostate of African American and Caucasian men. Lab Invest 1996; 74: 82A (Abstract 469).
88. deVere White RW et al. Racial differences in prostate cancer. J Urol 1996; 155: 529 (Abstract 875).
89. Hayes RB et al. Prostate cancer risk in US blacks and whites with a family history of prostate cancer. Int J Cancer 1995; 60: 361-364.
90. Smith JR et al. Major susceptibility locus for prostate cancer on chromosome 1 revealed by a genome-wide search. Science 1996; 274: 1371-1374.
91. Wideroff L et al. Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 1996; 28: 117-123.